ABSTRACT
Individuals with monoallelic pathogenic variants in the histone lysine methyltransferase DOT1L display global developmental delay and varying congenital anomalies. However, the impact of monoallelic loss of DOT1L remains unclear. Here, we present a largely female cohort of 11 individuals with DOT1L variants with developmental delays and dysmorphic facial features. We found that DOT1L variants include missense variants clustered in the catalytic domain, frameshift, and stop-gain variants. We demonstrate that specific variants cause loss of methyltransferase activity and therefore sought to define the effects of decreased DOT1L function. Using RNA-sequencing of cultured neurons and single nucleus RNA-sequencing of mouse cortical tissue, we found that partial Dot1l depletion causes sex-specific transcriptional responses and disrupts transcription of synaptic genes. Further, Dot1l loss alters neuron branching and expression of synaptic proteins. Lastly using zebrafish and mouse models, we found behavioral disruptions that include sex-specific deficits in mice. Overall, we define how DOT1L loss leads to neurological dysfunction by demonstrating that partial Dot1l loss impacts transcription, neuron morphology, and behavior across multiple models and systems.
Competing Interest Statement
KV has received honoraria as an advisory board member, travel expenses and speaker fees from Biogen, Santhera, Orchard, ITF and Novartis, outside the submitted work. JLM is an employee of and may own stock in GeneDx, LLC. All other authors declare they have no competing interests.
Funding Statement
NIH NINDS grant 1F31NS129242 (MM). NIH/NICHD grant P50 HD105354, Intellectual and Developmental Disabilities Research Center (research support). NIH NINDS grant 1R01NS134755 (EK). NIH NIMH grant 1DP2MH129985 (MB, EK). NIH NIMH grant R00MH111836 (MB, EK). Klingenstein-Simons Fellowship from the Esther A. & Joseph Klingenstein Fund (MB, EK). Simons Foundation (MB, EK). Alfred P. Sloan Foundation Research Fellowship FG-2020-13529 (MB, EK). Brain and Behavior Research Foundation NARSAD Young Investigator Award (MB, EK). SickKids Research Institute (ARD). Azrieli Precision Child Health Platform (ARD). NIHR Manchester Biomedical Research Centre NIHR203308 (SB). MRC Epigenomics of Rare Diseases Node MR/Y008170/1 (SB). Miguel Servet program from Instituto de Salud Carlos III, Spain CP22/00141 (DNB). Netherlands Organisation for Scientific Research ZonMw Vidi, grant 09150172110002 (TSB). EpilepsieNL (TSB). CURE Epilepsy (TSB). NIH NINDS grant K08NS135125 (PDC). University of Pennsylvania Autism Spectrum Program of Excellence (ASPE) (JM, PDC). ANID-Chile Fondecyt grant #1211411 (GMR, VF). "Joan Oro" of the Secretary of Universities and Research of the Department of Research and Universities of the Government of Catalonia with code 2024 FI-1 00075 (BEA). European Union (BEA).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Human subject studies were approved consistent with the principles of research ethics and the legal requirements of the lead clinician author jurisdiction (The Hospital for Sick Children, Canada). Voluntary, informed consent was obtained from human participants, consistent with the institutional principles of research ethics and the legal requirements of each referring author jurisdiction. Ethical approvals were obtained for participation, phenotyping, sample collection and generation/derivation of affected individual and control fibroblasts (IRB#16-013278_AM118, Childrens Hospital of Philadelphia). The authors also confirm that human research participants provided written informed consent for publication of the images in Fig. 1.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The exome/genome sequencing will be made available upon request provided that privacy and consent criteria are preserved. RNA-sequencing and single nucleus RNA-sequencing data generated in this study can be accessed under the following GEO accession number GSE279978. Variants p.I85M (SCV004169212), E134K (SCV004169195), and Gln598* (SCV003804054) are available on ClinVar. All data are available in the main text or the supplementary materials. Any additional data will be made available within two weeks upon request to corresponding author.
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE279978
